CACNA1A Gene Familial Hemiplegic Migraine Type 1 Genetic Test
At DNA Labs UAE, we offer the CACNA1A Gene Familial Hemiplegic Migraine Type 1 Genetic Test for individuals experiencing symptoms related to this condition. This test can help diagnose and manage familial hemiplegic migraine type 1 (FHM1), a rare form of migraine.
Test Details
The CACNA1A gene is associated with FHM1, which is characterized by severe headaches accompanied by temporary paralysis on one side of the body, visual disturbances, and other neurological symptoms. Our NGS (next-generation sequencing) technology allows us to analyze the DNA sequence of the CACNA1A gene to identify any mutations or variations that may be present.
Components and Price
The cost of the CACNA1A Gene Familial Hemiplegic Migraine Type 1 Genetic Test is AED 4400.0. The sample condition required for testing includes blood, extracted DNA, or one drop of blood on an FTA card.
Test Method and Type
We use NGS technology to perform the CACNA1A Gene Familial Hemiplegic Migraine Type 1 Genetic Test. This test falls under the category of neurological disorders and is conducted in our Genetics department.
Doctor and Pre-Test Information
A neurologist will oversee the CACNA1A Gene Familial Hemiplegic Migraine Type 1 Genetic Test. Before the test, it is important to provide the clinical history of the patient who is undergoing the test. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected by FHM1.
Report Delivery and Timeframe
The report for the CACNA1A Gene Familial Hemiplegic Migraine Type 1 Genetic Test will be delivered within 3 to 4 weeks after the sample is received and analyzed.
Benefits of Genetic Testing
NGS genetic testing is a powerful tool that can not only confirm a diagnosis of FHM1 but also provide valuable information for managing the condition. For example, individuals with FHM1 may be advised to avoid certain triggers that can trigger migraines, such as stress, bright lights, or certain foods. Genetic testing can also identify other genetic factors that may contribute to the development of migraines or other neurological conditions, helping guide treatment decisions and improve outcomes.
Don’t let migraines control your life. Get the CACNA1A Gene Familial Hemiplegic Migraine Type 1 Genetic Test at DNA Labs UAE today and take control of your health.
Test Name | CACNA1A Gene Familial hemiplegic migraine type 1 Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Neurological Disorders |
Doctor | Neurologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for CACNA1A Gene Familial hemiplegic migraine type 1 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with CACNA1A Gene Familial hemiplegic migraine type 1 |
Test Details |
The CACNA1A gene is associated with a rare form of migraine called familial hemiplegic migraine type 1 (FHM1). This condition is characterized by severe headaches that are often accompanied by temporary paralysis on one side of the body (hemiplegia), visual disturbances, and other neurological symptoms. NGS (next-generation sequencing) genetic testing is a powerful tool that can be used to identify mutations in the CACNA1A gene that may be responsible for FHM1. This type of testing involves analyzing the DNA sequence of the gene to identify any changes or variations that may be present. If a mutation is identified, it can help confirm a diagnosis of FHM1 and provide valuable information for managing the condition. For example, individuals with FHM1 may be advised to avoid certain triggers that can trigger migraines, such as stress, bright lights, or certain foods. NGS genetic testing can also be used to identify other genetic factors that may be contributing to the development of migraines or other neurological conditions. This information can help guide treatment decisions and improve outcomes for individuals with these conditions. |